Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics develops peptide-based therapeutics using a proprietary discovery platform, with programs spanning inflammation and immunology, hematology and metabolic disease. Company news centers on ICOTYDE™ (icotrokinra), an oral IL-23 receptor-targeted peptide approved for moderate-to-severe plaque psoriasis, and rusfertide, a hepcidin mimetic peptide for polycythemia vera developed with Takeda.
Recurring updates also cover collaboration economics with Johnson & Johnson's Janssen Biotech and Takeda, clinical and regulatory milestones, R&D spending on wholly owned discovery programs, financial results, investor conference participation and equity-based inducement awards under Nasdaq rules.
Protagonist Therapeutics (Nasdaq: PTGX) reported that on July 15, 2026, it granted equity inducement awards to three recently hired employees under its Amended and Restated Inducement Plan, originally adopted May 29, 2018 and amended in 2020 and 2022.
The employees received, in aggregate, options for 12,600 shares of common stock and RSUs for 3,330 shares. The stock options have an exercise price of $135.46, equal to the July 15, 2026 Nasdaq Global Market closing price. Options vest over four years (25% after one year, then monthly over three years), while RSUs vest 25% annually over four years. The compensation committee approved these awards as material inducements to employment in accordance with Nasdaq Rule 5635(c)(4).
Protagonist Therapeutics (Nasdaq: PTGX) granted stock-based inducement awards on June 30, 2026 to three new employees under its Inducement Plan. Awards include options for 8,650 shares and 2,275 RSUs at an exercise price of $122.58 per share.
Options vest over four years, with 25% after one year and the rest monthly over three years. RSUs vest in four equal annual installments. The compensation committee approved these grants as material inducements under Nasdaq Rule 5635(c)(4).
Protagonist Therapeutics (Nasdaq:PTGX) granted equity inducement awards to three new employees on June 15, 2026, under its Amended and Restated Inducement Plan.
The grants total 14,800 stock options at a $112.46 exercise price and 3,900 RSUs, with four-year vesting schedules, approved under Nasdaq Rule 5635(c)(4).
Protagonist Therapeutics (PTGX) will present four abstracts on rusfertide in polycythemia vera at the 2026 European Hematology Association Congress in Stockholm, June 11-14, 2026.
Data span the Phase 3 VERIFY trial and long-term Phase 2 REVIVE and THRIVE extension studies, covering efficacy, safety, cytoreductive therapy use, thromboembolic and progression events, and patient-reported outcomes.
Protagonist Therapeutics (Nasdaq:PTGX) announced that President and CEO Dinesh V. Patel, Ph.D., will participate in two June 2026 healthcare investment conferences.
He will join fireside chats at the Jefferies Global Healthcare Conference in New York on June 3 at 9:55 A.M. ET and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 10 at 9:20 A.M. ET, both accessible via webcast. Replay of the presentations will be available on the company’s investor relations website for one year.
Protagonist (Nasdaq:PTGX) reported Q1 2026 results and a corporate update, highlighting FDA approval of ICOTYDE, a $50.0 million milestone payment, and FDA Priority Review for rusfertide with a PDUFA date in Q3 2026. The company exercised a $200.0 million rusfertide opt-out fee and expects increased downstream economics, including up to $775.0 million in sales milestones and 14%–29% royalties. Cash, cash equivalents and marketable securities were $620.3 million as of March 31, 2026, projected to fund operations through at least 2028. PN-881 and PN-477 clinical progress continues.
Protagonist (Nasdaq:PTGX) exercised its U.S. opt-out right under the Takeda collaboration for rusfertide, making Protagonist eligible for $200 million upon election and another $200 million upon FDA approval.
U.S. approval would add a $75 million milestone, bringing opt-out-linked cash to $475 million, and the company remains eligible for up to $975 million in milestones plus tiered worldwide royalties of 14%–29% (weighted-average ~21% at $1.5B sales). PDUFA target action is Q3 2026.
Protagonist Therapeutics (Nasdaq:PTGX) granted inducement awards on April 15, 2026 to two newly hired employees under its Amended and Restated Inducement Plan.
The awards total options for 55,425 shares and RSUs for 14,425 shares; option exercise price is $105.44, equal to the April 15, 2026 closing price. Vesting spans four years. Awards were approved by the compensation committee and granted in accordance with Nasdaq Rule 5635(c)(4).
Protagonist (Nasdaq:PTGX) reported one-year Phase 3 results for ICOTYDE in moderate-to-severe plaque psoriasis presented at AAD 2026 showing durable complete skin clearance, a favorable safety profile, and oral once-daily dosing. Adolescents: ~60% PASI100, 86% PASI90; 92% maintained PASI90 from Week 24 to 52.
ICOTYDE demonstrated increased PASI100 from Week 24 to Week 52, no new safety signals through Week 52, and lower overall adverse event and infection rates versus deucravacitinib through Week 24. J&J holds commercialization rights; Protagonist may receive tiered royalties and milestone payments.
Protagonist Therapeutics (NASDAQ:PTGX) announced U.S. FDA approval of ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in adults and patients 12+ weighing ≥40 kg. Approval followed four Phase 3 studies (2,500 patients) showing high efficacy and favorable safety. Johnson & Johnson will commercialize ICOTYDE.
Approval triggers a $50 million milestone to Protagonist; the company is eligible for 6–10% royalties and up to $580 million additional milestones. A webcast and call are scheduled for March 18 at 8:30 am ET.